Commuters as well as other cyclists visit energizer stations around the Bay Area SAN FRANCISCO, May 26, 2023 /PRNewswire/ -- Thursday, May 18's weather was perfect for biking, and thousands came...

Following the G7 Summit and in collaboration with ICAN - Virtual Screening of Rare First Person Account of a Hiroshima Survivor to Remind the World of The Horrors of Nuclear War and The Power of...

Bloomz, the leading parent-teacher communication app, has announced it will be attending the PAIU Education Conference as a vendor. The conference will take place from May 31st through June 2nd....

Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, May 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that...

The "Critical Minerals & Energy Investment North America Conference and Exhibition" conference has been added to ResearchAndMarkets.com's offering. Explore North America's Critical Minerals &...

SOFAR, the global leading supplier of PV & ESS solutions, released multiple, competitive solar and energy storage innovations globally at SNEC 2023, fueling an accelerating clean transition to...

BOE breaks through the resolution limit of traditional process, leading the new trend of the quantum dot display industry LOS ANGELES, May 26, 2023 /PRNewswire/ -- Recently, BOE Technology Group...

Sunyard Technology, the leading global payment solution provider, has successfully shown the latest, cutting-edge payment solutions at the just past Seamless Middle East, talking about the...

- Introducing "Project PV" to transport various physical objects to virtual worlds and create new forms of entertainment at the world's leading XR conference - TOKYO, May 26, 2023 /PRNewswire/ --...

Research on a heart medication for childhood cancer survivors and new immunotherapies for blood and solid tumors will be presented. LOS ANGELES, May 26, 2023 /PRNewswire/ -- City of Hope, one of...

– Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care – SAN FRANCISCO, May 26, 2023...

Autodesk, Inc. (NASDAQ: ADSK) today announced its executives will be speaking at the following investor conference: June 7, 2023 Rosenblatt Securities 3rd Annual Technology Summit: The Age of AI A...

Exact Sciences' approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program...

SID Display Week 2023, an influential event hailed as the "Oscars" in the display industry, was held in Los Angeles, the United States, from May 23 to 25, 2023. Mr. Chen Yanshun, Chairman of BOE,...

The "5th Annual Circulating Biomarkers and Extracellular Vesicles Europe 2023" conference has been added to ResearchAndMarkets.com's offering. The Circulating Biomarkers & Extracellular Vesicles...

The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors The...

Vial, a global tech-first CRO providing next-generation clinical trial management services, announced it will be a sponsor and exhibitor at the 2023 BIO International Convention in Boston, MA,...

Research Presented by Dr. Thomas Stricker Suggests Oncologists Should Switch to Targeted Treatment if Biomarker Testing Identifies Actionable Mutation Even After First-Line Treatment on...

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in...

Physician-scientists will present expansive new cancer research, including 33 accepted abstracts NEW BRUNSWICK, N.J., May 25, 2023 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey and...

The company serves as a model for businesses that aim to support veterans, achieving a 240+% increase in veteran hires since 2020 and expanding initiatives to extend assistance in 2023 and beyond...

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in...

BTX-9341 demonstrated potent degradation of CDK4/6 and tumor growth regression in resistant cells in preclinical breast cancer models, along with robust blood brain barrier penetration SOS1...

Vorasidenib data from the INDIGO Phase 3 trial adds to the body of evidence on the impact of targeting the IDH mutation in cancer with the first major advancement in low-grade glioma in 23 years...

- New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment SEOUL, South Korea, May 25, 2023...